A new laboratory technique that will accelerate development of vaccines to protect people from a wide range of diseases has been reported by an international team of scientists.
Normally, vaccines induce B-lymphocytes or B-cells of the body's immune system to produce antibodies that fight against invading pathogens like viruses.
In the new study, researchers have developed a method to rapidly produce specific human antibodies in the laboratory itself from B-cells isolated from patient blood samples and by replicating the same processes these cells use in the body to prevent infections.
The technique, reported in the Journal of Experimental Medicine, could potentially accelerate the development of new vaccines by allowing the efficient evaluation of candidate target antigens, it is claimed.
The researchers, from Francis Crick Institute in London and the Ragon Institute of Massachusetts General Hospital in the US, successfully demonstrated their approach using various bacterial and viral antigens and proteins from several strains of influenza A.
In each case, the researchers were able to produce specific high-affinity antibodies in just a few days and were also able to generate antibodies against HIV (which causes AIDS) from B-cells isolated from HIV-free patients.
The scientists believe their approach will help researchers generate therapeutic antibodies within a shorter time frame in the laboratory for the treatment of infectious diseases and other conditions such as cancer.
(K.S. Jayaraman is a senior journalist who writes on scientific issues. He can be contacted at killugudi@hotmail.com)
--IANS
ksj/vm
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
